CRSP
CRISPR Therapeutics AG NASDAQ Listed Oct 19, 2016$52.42
Mkt Cap $5.1B
52w Low $34.12
41.3% of range
52w High $78.48
50d MA $52.41
200d MA $56.33
P/E (TTM)
-8.0x
EV/EBITDA
-8.7x
P/B
2.4x
Debt/Equity
0.2x
ROE
-30.3%
P/FCF
-13.6x
RSI (14)
—
ATR (14)
—
Beta
1.79
50d MA
$52.41
200d MA
$56.33
Avg Volume
1.9M
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Baarerstrasse 14 · Zug 6300 · CH
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 12, 2026 | AMC | -1.15 | -1.37 | -19.1% | 48.93 | +1.7% | +8.5% | +0.2% | +0.7% | +2.1% | -2.2% | — |
| Nov 10, 2025 | AMC | -1.26 | -1.17 | +7.1% | 54.58 | -0.7% | +1.2% | -5.5% | -2.1% | +2.8% | +5.3% | — |
| Aug 4, 2025 | AMC | -1.47 | -1.29 | +12.2% | 59.59 | -8.9% | -6.7% | +1.3% | -0.7% | -1.7% | +0.7% | — |
| May 6, 2025 | AMC | -1.27 | -1.58 | -24.4% | 33.16 | +4.1% | +3.3% | +5.5% | -1.4% | +5.5% | -1.0% | — |
| Feb 11, 2025 | AMC | -1.15 | -0.44 | +61.7% | 39.62 | +2.7% | +9.3% | +0.4% | +14.3% | +5.0% | +1.5% | — |
| Nov 5, 2024 | AMC | -1.33 | -1.01 | +24.1% | 50.36 | +2.9% | +0.7% | +2.3% | -0.5% | +6.3% | -7.5% | — |
| Aug 5, 2024 | AMC | -1.37 | -1.49 | -8.8% | 49.66 | +1.1% | -0.7% | -4.2% | +1.2% | -1.8% | -0.2% | — |
| May 8, 2024 | AMC | -1.63 | -1.43 | +12.3% | 53.29 | -2.2% | +0.5% | -4.4% | +8.8% | +0.1% | +2.2% | — |
| Feb 21, 2024 | AMC | -0.07 | 1.10 | +1671.4% | 82.41 | -0.5% | +4.6% | -2.6% | +2.5% | +3.6% | -1.6% | — |
| Nov 6, 2023 | AMC | -1.98 | -1.41 | +28.8% | 51.58 | +1.7% | +13.6% | -6.6% | -6.3% | +3.7% | -2.2% | — |
| Aug 7, 2023 | AMC | -2.18 | -0.98 | +55.0% | 48.34 | +1.9% | +9.7% | -4.0% | -1.7% | -0.8% | -2.5% | — |
| May 8, 2023 | AMC | -1.67 | -0.67 | +59.9% | 55.96 | +0.9% | +13.3% | +6.9% | -2.6% | -3.2% | +3.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 17 | Piper Sandler | Maintains | Overweight → Overweight | — | $48.42 | $48.90 | +1.0% | +3.4% | -4.8% | -1.6% | -1.5% | +1.4% |
| Feb 17 | Chardan Capital | Maintains | Buy → Buy | — | $53.07 | $53.00 | -0.1% | +0.2% | +0.7% | +2.1% | -2.2% | +1.0% |
| Feb 13 | Evercore ISI | Maintains | Outperform → Outperform | — | $48.93 | $49.74 | +1.7% | +8.5% | +0.2% | +0.7% | +2.1% | -2.2% |
| Feb 13 | TD Cowen | Maintains | Hold → Hold | — | $48.93 | $49.74 | +1.7% | +8.5% | +0.2% | +0.7% | +2.1% | -2.2% |
| Feb 13 | Needham | Maintains | Buy → Buy | — | $48.93 | $49.74 | +1.7% | +8.5% | +0.2% | +0.7% | +2.1% | -2.2% |
| Jan 30 | Citizens | Maintains | Market Outperform → Market Outperform | — | $53.35 | $52.12 | -2.3% | -6.4% | +2.7% | +1.3% | -3.5% | -8.6% |
| Dec 23 | Needham | Maintains | Buy → Buy | — | $57.91 | $57.10 | -1.4% | -2.5% | +0.4% | -2.9% | -2.0% | -1.4% |
| Dec 23 | Citizens | Maintains | Market Outperform → Market Outperform | — | $57.91 | $57.10 | -1.4% | -2.5% | +0.4% | -2.9% | -2.0% | -1.4% |
| Nov 26 | Chardan Capital | Maintains | Buy → Buy | — | $53.57 | $53.63 | +0.1% | -0.5% | +0.3% | -2.4% | -1.1% | +8.5% |
| Nov 12 | Citigroup | Maintains | Buy → Buy | — | $55.21 | $55.31 | +0.2% | -5.5% | -2.1% | +2.8% | +5.3% | -3.3% |
| Nov 11 | Baird | Maintains | Neutral → Neutral | — | $54.58 | $54.18 | -0.7% | +1.2% | -5.5% | -2.1% | +2.8% | +5.3% |
| Nov 11 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $54.58 | $54.18 | -0.7% | +1.2% | -5.5% | -2.1% | +2.8% | +5.3% |
| Nov 10 | Needham | Maintains | Buy → Buy | — | $55.12 | $58.06 | +5.3% | -1.0% | +1.2% | -5.5% | -2.1% | +2.8% |
| Oct 17 | BofA Securities | Maintains | Buy → Buy | — | $68.43 | $67.55 | -1.3% | +1.1% | +7.0% | -2.2% | -8.0% | +1.0% |
| Oct 10 | Needham | Maintains | Buy → Buy | — | $74.92 | $77.33 | +3.2% | -2.5% | -6.5% | +1.6% | +3.5% | -4.7% |
| Sep 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $62.10 | $61.63 | -0.8% | -2.2% | +0.5% | -1.2% | +2.2% | +3.4% |
| Aug 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $56.34 | $56.35 | +0.0% | -0.7% | -1.7% | +0.7% | +2.1% | +1.3% |
| Aug 6 | Barclays | Maintains | Equal Weight → Equal Weight | — | $55.59 | $55.59 | +0.0% | +1.3% | -0.7% | -1.7% | +0.7% | +2.1% |
| Aug 5 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $59.59 | $54.30 | -8.9% | -6.7% | +1.3% | -0.7% | -1.7% | +0.7% |
| Aug 5 | Chardan Capital | Maintains | Buy → Buy | — | $59.59 | $54.30 | -8.9% | -6.7% | +1.3% | -0.7% | -1.7% | +0.7% |
| Jul 22 | BofA Securities | Maintains | Buy → Buy | — | $65.33 | $64.68 | -1.0% | +0.9% | +3.4% | -3.1% | -2.0% | -1.6% |
| Jul 8 | Needham | Maintains | Buy → Buy | — | $51.19 | $51.32 | +0.3% | +7.1% | +9.6% | -1.8% | -3.7% | -0.7% |
| Jun 27 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $46.70 | $46.72 | +0.0% | +1.7% | +2.4% | -0.3% | +6.5% | +1.0% |
| Jun 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $46.70 | $46.72 | +0.0% | +1.7% | +2.4% | -0.3% | +6.5% | +1.0% |
| Jun 27 | Piper Sandler | Maintains | Overweight → Overweight | — | $46.70 | $46.72 | +0.0% | +1.7% | +2.4% | -0.3% | +6.5% | +1.0% |
| Jun 27 | Clear Street | Downgrade | Buy → Hold | — | $46.70 | $46.72 | +0.0% | +1.7% | +2.4% | -0.3% | +6.5% | +1.0% |
| Jun 26 | Needham | Maintains | Buy → Buy | — | $47.66 | $47.33 | -0.7% | -2.0% | +1.7% | +2.4% | -0.3% | +6.5% |
| Jun 26 | Chardan Capital | Maintains | Buy → Buy | — | $47.66 | $47.33 | -0.7% | -2.0% | +1.7% | +2.4% | -0.3% | +6.5% |
| May 21 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $39.25 | $38.80 | -1.1% | -5.8% | +1.5% | -1.8% | +1.9% | -0.9% |
| May 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $38.68 | $38.81 | +0.3% | +1.5% | -5.8% | +1.5% | -1.8% | +1.9% |
| May 20 | Needham | Maintains | Buy → Buy | — | $38.68 | $38.81 | +0.3% | +1.5% | -5.8% | +1.5% | -1.8% | +1.9% |
| May 9 | Barclays | Maintains | Equal Weight → Equal Weight | — | $36.14 | $36.39 | +0.7% | -1.4% | +5.5% | -1.0% | -4.4% | +2.0% |
| May 8 | Goldman Sachs | Maintains | Neutral → Neutral | — | $34.25 | $34.88 | +1.8% | +5.5% | -1.4% | +5.5% | -1.0% | -4.4% |
| May 7 | Chardan Capital | Maintains | Buy → Buy | — | $33.16 | $34.51 | +4.1% | +3.3% | +5.5% | -1.4% | +5.5% | -1.0% |
| May 7 | Needham | Maintains | Buy → Buy | — | $33.16 | $34.51 | +4.1% | +3.3% | +5.5% | -1.4% | +5.5% | -1.0% |
| Apr 9 | Needham | Maintains | Buy → Buy | — | $31.27 | $30.56 | -2.3% | +11.6% | -1.8% | +14.7% | -1.2% | +0.4% |
| Feb 19 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $52.22 | $52.40 | +0.3% | +1.5% | -4.9% | -5.0% | -2.8% | -4.4% |
| Feb 18 | Citigroup | Maintains | Buy → Buy | — | $49.72 | $52.25 | +5.1% | +5.0% | +1.5% | -4.9% | -5.0% | -2.8% |
| Feb 14 | Morgan Stanley | Maintains | Underweight → Underweight | — | $43.49 | $46.21 | +6.3% | +14.3% | +5.0% | +1.5% | -4.9% | -5.0% |
| Feb 14 | Evercore ISI | Upgrade | In Line → Outperform | — | $43.49 | $46.21 | +6.3% | +14.3% | +5.0% | +1.5% | -4.9% | -5.0% |
| Feb 13 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $43.30 | $43.70 | +0.9% | +0.4% | +14.3% | +5.0% | +1.5% | -4.9% |
| Feb 13 | Chardan Capital | Maintains | Buy → Buy | — | $43.30 | $43.70 | +0.9% | +0.4% | +14.3% | +5.0% | +1.5% | -4.9% |
| Feb 13 | Stifel | Maintains | Hold → Hold | — | $43.30 | $43.70 | +0.9% | +0.4% | +14.3% | +5.0% | +1.5% | -4.9% |
| Feb 13 | Goldman Sachs | Maintains | Neutral → Neutral | — | $43.30 | $43.70 | +0.9% | +0.4% | +14.3% | +5.0% | +1.5% | -4.9% |
| Feb 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $43.30 | $43.70 | +0.9% | +0.4% | +14.3% | +5.0% | +1.5% | -4.9% |
| Feb 12 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $39.62 | $40.67 | +2.7% | +9.3% | +0.4% | +14.3% | +5.0% | +1.5% |
| Feb 12 | Needham | Maintains | Buy → Buy | — | $39.62 | $40.67 | +2.7% | +9.3% | +0.4% | +14.3% | +5.0% | +1.5% |
| Feb 12 | Truist | Maintains | Buy → Buy | — | $39.62 | $40.67 | +2.7% | +9.3% | +0.4% | +14.3% | +5.0% | +1.5% |
| Feb 12 | Barclays | Maintains | Equal Weight → Equal Weight | — | $39.62 | $40.67 | +2.7% | +9.3% | +0.4% | +14.3% | +5.0% | +1.5% |
| Jan 14 | Needham | Maintains | Buy → Buy | — | $38.85 | $39.62 | +2.0% | -1.3% | +1.8% | +3.2% | +0.6% | +2.4% |
No insider trades available.
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
CRSP signed a material agreement, but details are incorporated by reference, making immediate impact assessment difficult—investors should review the full filing to understand strategic implications.
Mar 16
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
This 8-K filing contains only signature blocks without disclosing the actual material event, leaving investors unable to assess what news CRSP announced or its stock impact.
Mar 11
8-K
CRISPR Therapeutics AG -- 8-K Filing
CRISPR Therapeutics reported full-year 2025 financial results showing steady progress across its pipeline, though specific revenue or earnings impacts require reviewing complete filing details.
Feb 12
Data updated apr 25, 2026 3:21am
· Source: massive.com